A t first glance, psoriasis is a skin disease: Skin symptoms likely led to your diagnosis, and if you’ve dealt with the stigma of psoriasis from others, it was probably because of visible skin lesions ...

Adults with psoriatic arthritis saw early improvements in their symptoms and key health-related quality-of-life measures with ...

Jenifer Soung, MD, fo Southern California Dermatology, discussed how glucagon-like peptide-1 receptor agonists aid in treating patients with psoriatic disease. Captions are auto-generated.

Psoriasis is a chronic inflammatory immune-cell mediated disease, mediated by cross talk between epidermal keratinocytes, dermal vascular cells, and immunocytes. Psoriatic plaques are well defined and ...

Certain things, like your genes, can increase your risk for psoriatic arthritis. If you have a first-degree relative with psoriatic arthritis, you have 39 times the risk of developing it. Other risks ...

Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.

Researchers have identified a new potential strategy for inhibiting inflammation in both psoriasis and psoriatic arthritis. The corresponding study was published in the Annals of the Rheumatic ...

Depression symptoms are often underdiagnosed and undertreated in patients with psoriasis and psoriatic arthritis, contributing to a worsened quality of life (QOL). However, a recent study found that ...

As both a dermatologist and psychologist, I have studied the relationship between mental health and psoriatic disease for years. Many people don’t realize psoriatic disease affects more than just your ...

The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active ...

Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...